Core Insights - The company, Weilan Bio, was established on February 23, 2005, and went public on January 16, 2019, on the Shanghai Stock Exchange, with its registered and office locations in Shandong Province. It is a representative enterprise in the enzyme preparation and probiotic fields in China, with notable advantages in technology research and development [1] Financial Performance - For Q3 2025, Weilan Bio reported a revenue of 1.016 billion yuan, ranking 14th out of 24 in the industry. The top two competitors, Meihua Biological and Xinhengcheng, reported revenues of 18.215 billion yuan and 16.642 billion yuan, respectively, while the industry average was 357.1 million yuan [2] - The net profit for the same period was 82.93 million yuan, placing the company 15th in the industry. The leading competitors reported net profits of 5.354 billion yuan and 3.025 billion yuan, with the industry average at 539 million yuan [2] Financial Ratios - As of Q3 2025, Weilan Bio's debt-to-asset ratio was 37.49%, down from 38.62% year-on-year, which is higher than the industry average of 28.46% [3] - The company's gross profit margin for Q3 2025 was 44.45%, slightly up from 44.18% year-on-year, and also above the industry average of 28.77% [3] Management and Shareholder Information - The chairman and general manager, Chen Gang, received a salary of 1.97 million yuan in 2024, an increase of 499,300 yuan from 2023 [4] - As of September 30, 2025, the number of A-share shareholders decreased by 22.70% to 17,000, while the average number of circulating A-shares held per account increased by 29.36% to 14,900 [5] Strategic Outlook - According to Minsheng Securities, Weilan Bio's revenue and net profit showed fluctuations in the first half of 2025, with Q2 performance improving. The company is focusing on innovation strategies, with significant results in food probiotics and animal health products. The capacity layout is nearing completion, enhancing multi-business synergy [5] - Guoxin Securities noted that the company expects steady revenue growth in 2024 and Q1 2025, with the capacity layout nearly finished. The R&D-driven gross margin for enzyme products is expected to continue rising, benefiting from market expansion due to alternatives to feed antibiotics [5]

Core Viewpoint - Juxing Agriculture and Animal Husbandry, established in December 2013 and listed in December 2017, is a leading integrated enterprise in breeding, feed production, and leather business in China, with a full industry chain advantage and advanced breeding technology [1] Business Performance - In Q3 2025, Juxing's revenue was 5.639 billion, ranking 6th among 12 companies in the industry, significantly lower than the top company Muyuan Foods at 111.79 billion and second-ranked New Hope at 80.504 billion, but slightly above the industry median of 5.515 billion and below the average of 25.654 billion [2] - The main business revenue composition includes 3.432 billion from pig farming (92.32%), 179 million from feed (4.80%), 101 million from leather products (2.72%), and 5.9249 million from other sources (0.16%) [2] - The net profit for the period was 113 million, ranking 7th in the industry, far below Muyuan Foods' 15.112 billion and Wen's 5.417 billion, and also below the industry median of 186 million and average of 1.879 billion [2] Financial Ratios - As of Q3 2025, Juxing's debt-to-asset ratio was 66.62%, up from 60.81% year-on-year and above the industry average of 57.82%, indicating increased debt pressure [3] - The gross profit margin for Q3 2025 was 10.44%, down from 17.84% year-on-year and below the industry average of 14.00%, reflecting a decline in profitability [3] Executive Compensation - The chairman, Duan Lifeng, received a salary of 1.476 million in 2024, an increase of 399,500 from 2023 [4] - The general manager, Tang Chunxiang, received a salary of 1.4028 million in 2024, an increase of 953,000 from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 23.11% to 44,700, with an average holding of 11,400 circulating A-shares, down by 18.77% [5] - Among the top ten circulating shareholders, the Guotai CSI Livestock Breeding ETF ranked sixth with 5.6501 million shares, an increase of 2.0204 million shares from the previous period [5] Production and Future Outlook - Juxing's pig output increased steadily to 2.9342 million heads in Q1-Q3 2025, a year-on-year increase of 69%, although pig prices fell, leading to losses in Q3 [6] - The company is expected to achieve revenues of 7.541 billion, 7.917 billion, and 8.733 billion from 2025 to 2027, with net profits of 120 million, 448 million, and 839 million respectively [6]